The proposed acquisition of Eczacıbaşı-Monrol will: Build on existing partnership in Lu-177 creating a leading manufacturer of the isotopeAdd 12 PET sites to Curium’s existing network in geographies where Curium is not present todayAdd SPECT manufacturing capabilities and extensive logistics infrastructure to CuriumBenefit patients with strengthened reliability for diagnostic and therapeutic solutions PARIS, April 08, 2024 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced today that it has entered into an agreement with Eczacıbaşı Holding and Bozlu Group for the acquisition of Eczacıbaşı-Monrol Nuclear Product Co.

拟议收购Eczacıbaşıı-Monrol将：建立在Lu-177现有合作伙伴关系的基础上，创建一家领先的同位素生产商，并在Curium目前不存在的地区为Curium的现有网络建立12个PET站点，为Curium患者提供SPECT制造能力和广泛的物流基础设施，以增强诊断和治疗解决方案的可靠性巴黎，2024年4月8日（环球通讯社）——Curium，世界核医学领导者，今天宣布，它已与Eczacıbaşıı控股和Bozlu集团达成协议，收购Eczacıbaşı-Monrol核产品公司。

(Monrol), a dedicated specialist in nuclear medicine. The acquisition is expected to bring together highly complementary geographical footprints, lutetium-177 (Lu-177) capabilities, and PET & SPECT nuclear medicine infrastructure, as well as facilitate the development of cutting-edge radionuclides and radiopharmaceuticals pipelines for diagnostic and therapeutic purposes.

（Monrol），一位专注于核医学的专家。此次收购预计将汇集高度互补的地理足迹、lutetium-177（Lu-177）能力以及PET和SPECT核医学基础设施，并促进用于诊断和治疗目的的尖端放射性核素和放射性药物管道的开发。

Importantly, the acquisition will add significant Lu-177 manufacturing capacity to Curium to meet the growing demand for Lu-177 around the world for the benefit of more than 100,000 critically ill patients worldwide over the next five years. It will expand Curium’s PET footprint of 34 sites in Western Europe and Asia with the addition of 12 owned and partnered sites in Eastern Europe and MENA regions.

重要的是，此次收购将为Curium增加重要的Lu-177制造能力，以满足全球对Lu-177日益增长的需求，在未来五年内，全球将有超过100000名重症患者受益。它将扩大库里姆在西欧和亚洲34个地点的宠物足迹，并在东欧和中东和北非地区增加12个拥有和合作的地点。

In addition, Eczacıbaşı-Monrol’s manufacturing and logistics infrastructure in Istanbul, Turkey, will add significant scale to Curium’s vertically integrated production and distribution capabilities. Mr. Chaitanya Tatineni, Curium’s CEO International Markets commented: “We are extremely pleased to have reached an agreement for the acquisition of Eczacıbaşı-Monrol – buil.

此外，Eczacıbaşıı-Monrol在土耳其伊斯坦布尔的制造和物流基础设施将大大提高库里姆垂直一体化生产和分销能力。Curium国际市场首席执行官Chaitanya Tatineni先生评论道：“我们非常高兴就收购Eczacıbaşıı-Monrol–buil达成协议。